The Institute for Behavioral Medicine Research, The Ohio State University, Columbus, Ohio.
Department of Neuroscience, The Ohio State University, Columbus, Ohio.
Cancer. 2018 Oct 15;124(20):3990-3999. doi: 10.1002/cncr.31584. Epub 2018 Jul 5.
Increasing scientific attention is focused on the gut-brain axis, including the ability of the gastrointestinal (GI) tract to modulate central nervous system function. Changes in the intestinal microbiome can influence affective-like behavior, cognitive performance, fatigue, and sleep in rodents and humans. Patients with cancer who are receiving chemotherapy experience similar negative behavioral changes and concurrent GI symptoms. These chemotherapy comorbidities can be long-lasting and may reduce patients' quality of life and motivation to comply with treatment. This review summarizes the clinical and preclinical evidence supporting a role for the intestinal microbiome in mediating behavioral comorbidities through peripheral immune activation in patients with cancer who are receiving chemotherapy. In addition, evidence suggesting that targeted modification of the intestinal microbiome during cancer treatment could ameliorate associated behavioral comorbidities is reviewed.
越来越多的科学研究关注于肠道-大脑轴,包括胃肠道(GI)调节中枢神经系统功能的能力。肠道微生物组的变化可以影响啮齿动物和人类的情感样行为、认知表现、疲劳和睡眠。接受化疗的癌症患者也会经历类似的负面行为变化和胃肠道症状。这些化疗合并症可能持续时间较长,并可能降低患者的生活质量和治疗依从性。这篇综述总结了临床前和临床证据,支持肠道微生物组通过外周免疫激活在接受化疗的癌症患者中调节行为合并症的作用。此外,还回顾了在癌症治疗期间靶向修饰肠道微生物组可能改善相关行为合并症的证据。